Tags

Type your tag names separated by a space and hit enter

Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome.
Ann N Y Acad Sci. 2005 Jun; 1050:210-6.AN

Abstract

The objective of this study was to determine the prevalence of antibodies against alpha-fodrin (alpha-fodrin) of the immunoglobulin G (IgG) isotype in Sjögren's syndrome (SS), as defined by European Community Study Group (ESG) and ESG-modified criteria. We arrived at the prevalence and mean concentrations of IgG anti-alpha-fodrin antibodies using enzyme-linked immunosorbent assay (ELISA) in 507 patients with SS, primary SS (pSS), and secondary SS (sSS), classified according to either the ESG or the ESG-modified criteria. IgG anti-alpha-fodrin antibodies were detected in 6/507 (1.2%) and 4/228 (1.7%) of the SS group, according to the ESG or ESG-modified criteria, respectively. Similar prevalence was found for patients with pSS or sSS. Anti-Ro/SSA antibodies were present in 151/409 (36.9%) vs. 149/213 (70.0%) of the SS group, 85/195 (43.6%) vs. 83/101 (82.2%) of the pSS group, and 66/214 (30.8%) vs. 66/112 (58.9%) of the sSS group. Anti-La/SSB antibodies were detected in 77/403 (19.1%) vs. 73/212 (34.4%) of the SS group, 47/194 (24.2%) vs. 45/101 (44.5%) of the pSS group, and 30/209 (14.3%) vs. 28/111 (25.2%) of the sSS group. No clinical associations were found. Only two IgG anti-alpha-fodrin-positive sera were anti-Ro/SSA-negative. We conclude that IgG antibodies against alpha-fodrin are present in a small percentage of people with SS, pSS, and sSS. The lower prevalence in patients classified according to the ESG criteria reflects the lower specificity of these criteria. IgG anti-alpha-fodrin antibodies can be detected in some SS patients whose sera do not contain anti-Ro/SSA antibodies.

Authors+Show Affiliations

Department of Clinical Immunology, Gregorio Marañón Hospital, 28009 Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16014536

Citation

Ruiz-Tíscar, J L., et al. "Prevalence of IgG Anti-{alpha}-fodrin Antibodies in Sjogren's Syndrome." Annals of the New York Academy of Sciences, vol. 1050, 2005, pp. 210-6.
Ruiz-Tíscar JL, López-Longo FJ, Sánchez-Ramón S, et al. Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. Ann N Y Acad Sci. 2005;1050:210-6.
Ruiz-Tíscar, J. L., López-Longo, F. J., Sánchez-Ramón, S., Santamaría, B., Urrea, R., Carreño, L., Estecha, A., Vigil, D., Fernández-Cruz, E., & Rodríguez-Mahou, M. (2005). Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. Annals of the New York Academy of Sciences, 1050, 210-6.
Ruiz-Tíscar JL, et al. Prevalence of IgG Anti-{alpha}-fodrin Antibodies in Sjogren's Syndrome. Ann N Y Acad Sci. 2005;1050:210-6. PubMed PMID: 16014536.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. AU - Ruiz-Tíscar,J L, AU - López-Longo,F J, AU - Sánchez-Ramón,S, AU - Santamaría,B, AU - Urrea,R, AU - Carreño,L, AU - Estecha,A, AU - Vigil,D, AU - Fernández-Cruz,E, AU - Rodríguez-Mahou,M, PY - 2005/7/15/pubmed PY - 2005/10/20/medline PY - 2005/7/15/entrez SP - 210 EP - 6 JF - Annals of the New York Academy of Sciences JO - Ann N Y Acad Sci VL - 1050 N2 - The objective of this study was to determine the prevalence of antibodies against alpha-fodrin (alpha-fodrin) of the immunoglobulin G (IgG) isotype in Sjögren's syndrome (SS), as defined by European Community Study Group (ESG) and ESG-modified criteria. We arrived at the prevalence and mean concentrations of IgG anti-alpha-fodrin antibodies using enzyme-linked immunosorbent assay (ELISA) in 507 patients with SS, primary SS (pSS), and secondary SS (sSS), classified according to either the ESG or the ESG-modified criteria. IgG anti-alpha-fodrin antibodies were detected in 6/507 (1.2%) and 4/228 (1.7%) of the SS group, according to the ESG or ESG-modified criteria, respectively. Similar prevalence was found for patients with pSS or sSS. Anti-Ro/SSA antibodies were present in 151/409 (36.9%) vs. 149/213 (70.0%) of the SS group, 85/195 (43.6%) vs. 83/101 (82.2%) of the pSS group, and 66/214 (30.8%) vs. 66/112 (58.9%) of the sSS group. Anti-La/SSB antibodies were detected in 77/403 (19.1%) vs. 73/212 (34.4%) of the SS group, 47/194 (24.2%) vs. 45/101 (44.5%) of the pSS group, and 30/209 (14.3%) vs. 28/111 (25.2%) of the sSS group. No clinical associations were found. Only two IgG anti-alpha-fodrin-positive sera were anti-Ro/SSA-negative. We conclude that IgG antibodies against alpha-fodrin are present in a small percentage of people with SS, pSS, and sSS. The lower prevalence in patients classified according to the ESG criteria reflects the lower specificity of these criteria. IgG anti-alpha-fodrin antibodies can be detected in some SS patients whose sera do not contain anti-Ro/SSA antibodies. SN - 0077-8923 UR - https://www.unboundmedicine.com/medline/citation/16014536/Prevalence_of_IgG_anti_{alpha}_fodrin_antibodies_in_Sjogren's_syndrome_ L2 - https://doi.org/10.1196/annals.1313.022 DB - PRIME DP - Unbound Medicine ER -